Antifungal agents play a crucial role in combating fungal infections, which can affect various parts of the body. These agents are vital components of the broader category of antimicrobials, designed to target and eliminate fungi. One prominent class of antifungal agents is the azoles, which inhibit the synthesis of ergosterol, an essential component of fungal cell membranes. Common examples include fluconazole and itraconazole. Another class is the polyenes, exemplified by amphotericin B, which disrupts fungal cell membranes by binding to ergosterol. Echinocandins, a newer class, inhibit the synthesis of β-glucan in the fungal cell wall, leading to cell death. Caspofungin is a notable member of this group. Antifungal agents are utilized in various medical contexts, including the treatment of superficial infections like athlete's foot and more severe systemic infections such as candidemia. They are also crucial in preventing fungal infections in immunocompromised individuals, like those undergoing chemotherapy or organ transplantation.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain
Title : Gendered socioeconomic impacts of emerging infectious diseases: Insights from a mixed-methods study in Guinea
Stephanie Maltais, University of Montreal, Canada
Title : The role of social sciences in operationalizing the One Health approach: A case study of the DOPERAUS project in Guinea and the Democratic Republic of Congo
Stephanie Maltais, University of Montreal, Canada